Teleflex launches new Arrow® Pressure Injectable Midline Catheter Portfolio
September 27 2022 - 6:30AM
Teleflex Incorporated (NYSE: TFX) releases their new Arrow®
Pressure Injectable Midline portfolio in the US and Canada,
designed to help alleviate line identification confusion.
Clinicians can choose between the Arrowg+ard Blue Advance® Midline
with antimicrobial and antithrombogenic protection or the
traditional Arrow® Midline, both of which are available in single
and double lumen options.1,2
Without quick and easy identification between midlines and
PICCs, clinicians may mistakenly infuse medications through
midlines that should only be infused through a central venous
access device. These complications can cause disruption in patient
therapy and, if serious, could lead to line replacement.
Teleflex conducted extensive research with industry-leading
vascular access professionals to select the enhancements in the new
Arrow® Midline Catheters. Clinician-inspired updates to the
portfolio include:
- Eye catching, yellow colored
catheter features and labeling to help reduce line confusion and
promote patient safety
- A robust offering of 14 different
kit configurations, all with pressure injection capabilities to
facilitate procedural efficiency and mitigate risks
- A new Arrow® ergonomic trimmer that
allows for multiple precise cuts and easy visualization
- Premium components available such as
one-piece, full-body fenestrated drape, ultrasound probe cover with
gel, and Tegaderm™ CHG Securement Dressing
“The Arrowg+ard Blue Advance® Midline catheter portfolio
provides protection by reducing thrombus accumulation and the
primary pathogens responsible for most healthcare associated
infections1,2. With multiple levels of protection, critical
innovations, and a streamlined workflow, it’s the perfect solution
to deliver vital medications.” said Lisa Kudlacz, President and
General Manager, Vascular Access Division.
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular access, interventional
cardiology and radiology, anesthesia, emergency medicine, surgical,
urology and respiratory care. Teleflex employees worldwide are
united in the understanding that what we do every day makes a
difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®,
QuikClot®, Rüsch®, UroLift®, and Weck® – trusted brands united by a
common sense of purpose.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
References:
- In vitro data on
file 2010: AVER-004371 and AVER-004483. No correlation between in
vitro/in vivo testing methods and clinical outcomes have currently
been ascertained.
- As compared to
uncoated PICCs, intravascular ovine model inoculated with Staph
aureus: AVAR-000427. No correlation between in vitro/in vivo
testing methods and clinical outcomes have currently been
ascertained.
Rx only
Contraindication:
Clinical assessment of the patient must be completed to ensure
no contraindications exist. The Arrowg+ard Blue Advance® Midline is
contraindicated in the following areas:
- Patients with known hypersensitivity
to chlorhexidine
- In presence of device related
infections
- In presence of previous or current
thrombosis in the intended vessel or along the catheterized vessel
pathway.
No correlation between in vitro/in vivo testing methods and
clinical outcomes have currently been ascertained.
Tegaderm is a registered trademark of 3M or its affiliates.
Teleflex, the Teleflex logo, Arrow, Arrowg+ard Blue Advance,
Deknatel, LMA, Pilling, QuikClot, Rusch, UroLift, and Weck are
trademarks or registered trademarks of Teleflex Incorporated or its
affiliates, in the U.S. and/or other countries. All other marks are
the property of their respective owners.© 2022 Teleflex
Incorporated. All rights reserved. MC-008282
Contracts: Teleflex Incorporated:Lawrence
KeuschVice President, Investor Relations and Strategy
Development
John Hsu, CFAVice President, Investor Relations
investors.teleflex.com610-948-2836
Teleflex (NYSE:TFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Teleflex (NYSE:TFX)
Historical Stock Chart
From Jul 2023 to Jul 2024